3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
48
Lung Neoplasms
24
Carcinoma, Hepatocellular
24
Small Cell Lung Carcinoma
16
Urinary Bladder Neoplasms
12
Cholangiocarcinoma
12
Breast Neoplasms
10
Biliary Tract Neoplasms
10
Neoplasms
9
Neoplasm Metastasis
9
Liver Neoplasms
9
Pancreatic Neoplasms
7
Carcinoma
6
Endometrial Neoplasms
5
Colorectal Neoplasms
5
Triple Negative Breast Neoplasms
4
Non-Muscle Invasive Bladder Neoplasms
4
Neoplasms by Site
4
Gallbladder Neoplasms
4
Carcinoma, Transitional Cell
4
Stomach Neoplasms
3
Respiratory Tract Neoplasms
3
Ovarian Neoplasms
3
Carcinoma, Renal Cell
3
Bile Duct Neoplasms
3
Adenocarcinoma
3
Thyroid Neoplasms
2
Thoracic Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma
2
Interventions
Cisplatin
6
Platinum
5
Pemetrexed
5
1,2-diaminocyclohexaneplatinum II citrate
5
pembrolizumab
4
atezolizumab
2
Radiotherapy
2
Radiation
2
Nivolumab
2
Ipilimumab
2
Gemcitabine
2
Cyclophosphamide
2
Carboplatin
2
tremelimumab
1
methoxyamine
1
fludarabine
1
decitabine and cedazuridine drug combination
1
cediranib
1
anetumab ravtansine
1
aldesleukin
1
Trioxsalen
1
Tissue Banks
1
Radiotherapy, Intensity-Modulated
1
Proton Therapy
1
Phototherapy
1
Photochemotherapy
1
Pharmacogenomic Testing
1
Pharmaceutical Preparations
1
Interleukin-2
1
Influenza Vaccines
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Mesothelioma, Malignant
×
durvalumab
×
90 days
×
Clear all
No trials found.